DDInter460 DDInter1055
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Levofloxacin
Cytarabine {u} (Compound) binds {v} (Gene) SLC22A2
SLC22A2 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Gatifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Levofloxacin (Compound)
Cytarabine (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Levofloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Cytarabine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)